DBD vs AMPL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DBD · Diebold Nixdorf$58.27 ▼ 0.10%
AMPL · Amplitude$16.70 ▲ 3.73%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DBD -10.4%
- AMPL +55.6%
Head to head
| Metric | DBD | AMPL |
|---|---|---|
| Price | $58.27 | $16.70 |
| Change today | ▼ 0.10% | ▲ 3.73% |
| Market cap | $1.96B | $2.13B |
| Return, 3 months | -18.7% | +37.0% |
| Return, year to date | -14.2% | +44.2% |
| Return, 1 year | -9.7% | +66.8% |
| P/E (TTM) | 27.6 | -21.7 |
| P/B | 2.1 | 16.7 |
| P/E percentile vs own 5y | 86th | 5th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.2% | +21.2% |
| Net profit growth (YoY) | -83.0% | -40.3% |
| Gross margin | 25.0% | 72.4% |
| Operating margin | 6.2% | -27.0% |
| Net margin | 2.0% | -26.6% |
| Return on equity | 7.5% | -47.9% |
| Analyst target vs. price | +45.9% | -5.5% |
| Analyst buy share | 100% | 73% |
| RSI (14) | 38 | 57 |
| 30-day volatility | 54.6% | 44.3% |
| Max drawdown, 1 year | -39.3% | -53.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMPL is the largest of the group by market value.
- AMPL has returned the most over the past year.
- AMPL carries the lowest trailing P/E.
- AMPL is growing revenue fastest.
- DBD keeps the most profit per dollar of sales.
- AMPL has been the calmest stock over the last 30 days.